ArticleJournal of fluorescence2025
Facile and Sustainable Electrostatic Integration of Eosin Y Dye for the Assay of the Atomoxetine Drug Through the Enhancement of the RRS Phenomenon.
Article in Journal of fluorescence, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Sustainable Hybrid (NHLuminescence : the journal of biological and chemical luminescence · 2026Article
- Coupling MgSOScientific reports · 2026Article
- A fluorescence-off based approach for sensitive determination of bepotastine in pharmaceutical and biological matrices considering human safety aspects: sustainability assessment.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The suggested study follows specific protocols to guarantee that the atomoxetine drug analysis approach is environmentally friendly and sustainable. A number of recently created methods were used as prospective evidence for environmental sustainability and applicability, which is an essential point to emphasize. The current study introduces a new and very unique technology using ultrasensitive spectrofluorimetry to identify the atomoxetine (AXT) medication. A one-step, one-pot, direct spectrofluorimetric technique was used in this study's methodology, which was determined to be effective and environmentally sustainable for the drug's evaluation and validation. When AXT and EY reagent were mixed in an acidic setting, a highly resonant Rayleigh scattering product was promptly generated. The application of fluorimetric analysis was built on a novel theory that the augmentation in dye response subsequent to the addition of AXT was directly correlated to the resultant complex's molecular mass, as determined at a wavelength of 365 nm. The complexation progression caused a considerable rise in the molecular mass, from 292.82 (AXT
Indexed as
Identifiers
39407065What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.